- Home
- SITC vs WHWK Comparison
SITC vs WHWK Comparison
Compare SITC & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$4.26
HOLD
Current Price
$4.02
Company Overview
Basic Information| Metric | SITC | WHWK |
|---|---|---|
| Founded | 1965 | 2007 |
| Country | United States | United States |
| Employees | 155 | 23 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 240.9M | 233.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SITC | WHWK |
|---|---|---|
| Price | $4.26 | $4.02 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $8.00 | $7.50 |
| AVG Volume (30 Days) | ★ 998.4K | 573.3K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 123.63% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.09 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.91 | $1.57 |
| 52 Week High | $12.39 | $5.50 |
Technical Indicators
Market Signals| Indicator | SITC | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 36.23 | 43.93 |
| Support Level | N/A | $3.85 |
| Resistance Level | $5.63 | $4.38 |
| Average True Range (ATR) | 0.19 | 0.34 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 37.24 | 5.47 |
Price Performance
Historical Comparison SITC
WHWK
About SITC SITE Centers Corp.
SITE Centers Corp is a self-administered and self-managed REIT that operates as a fully integrated real estate company. The company is engaged in the business of owning, leasing, acquiring, redeveloping, developing, and managing shopping centers.
About WHWK Whitehawk Therapeutics Inc.
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.